Skip to main content
. 2010 Apr 26;38(16):5443–5455. doi: 10.1093/nar/gkq284

Figure 7.

Figure 7.

Confirmation of the initial BpaB-binding site in erp Operator 2 (A) Simultaneous EMSA using wild-type recombinant BpaB321 protein and both biotin-labeled wild-type erpAB1 probe b-WT and b-672. Probe b-672 is identical to b-WT except for deletion of 20 bp (Figure 1). Lane 1 contained only DNA. Lanes 2–12 contained BpaB321 at concentrations of 0.086, 0.18, 0.26, 0.35, 0.44, 0.53, 0.61, 0.70, 0.79, 0.86 and 1.1 µM, respectively. (B) EMSA using the radioactively labeled 40 bp probe r-40 (Figure 1). Lane 1 contained only DNA. Lanes 2–20 contained BpaB321 at concentrations of 0.40, 0.80, 1.0, 1.2, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 7.0, 10, 15, 20, 25, 30, 40 and 50 µM, respectively. (C) EMSA using the radioactively labeled 23-bp probe r-23, which encompasses the 20-bp sequence present in b-WT but absent from b-672 (see Figure 1). Lane 1 contained only DNA. Lanes 2–17 contained BpaB321 at concentrations of 0.40, 0.80, 1.0, 1.2, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 7.0, 10, 15, 20 and 30 µM, respectively.